Antibody discovery, 40x faster.

Aurora replaces the wet-lab screening loop with a generative model that proposes binders, ranks them, and sends only the top candidates to the bench.

Four discovery partners under contract. Two exclusive to Aurora.

03 Traction

Preclinical pipeline value

$12.4M

Up from $0.8M at first close

Q1 2024 Q3 2025 Q2 2026

Pilot result confirmed by partner lab

41 days from target to validated lead candidate, against an 18 month industry median.

Illustrative simulation. Returns are not guaranteed.

04 Team

Who is building it

SR

Dr. Sara Reyes

Chief Executive Officer

Ran antibody engineering at a top-five biologics group for nine years.

PhD, Stanford 14 patents 2 exits

MO

Dr. Marcus Oyelaran

Chief Science Officer

Built the machine learning platform behind three approved biologics.

PhD, MIT 31 papers Ex-Recursion

Eleven full-time staff. Nine hold doctorates.

05 Terms

42% funded

$2.1M

of $5M

Valuation cap $18M

Discount 20%

Minimum investment $100

Allocation left $2.9M

Instrument SCL Contract · Bitcoin L1 Anchored

Illustrative simulation. Returns are not guaranteed.